The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...
The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved ... patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency ...
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...
The FDA has approved Pfizer’s marstacimab (Hympavzi ... haemophilia therapy under FDA review is Sanofi’s fitusiran. This siRNA-based drug knocks down levels of the anticoagulant antithrombin ...
This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...
The FDA’s prescribing information states that Orlynvah should be used only to treat uUTI that are, or are thought to be, caused by susceptible bacteria. The drug wasn’t approved as a primary ...
The recommendation was published in a technical note in November 2021. In Brazil, Pfizer's drug is the only one with this technological platform. In other parts of the world, Moderna's vaccine ...
Baxter has received FDA approval to extend the shelf life of ... more than 825 truckloads of finished products from Baxter's North Cove, N.C. facility. A second bridge is set to open in early ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI ... 12 years of age and older with hemophilia A (congenital factor VIII deficiency ...